Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, provider
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:01am, Wednesday, 11'th Jun 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
01:36am, Wednesday, 11'th Jun 2025
AbbVie Inc. (NYSE:ABBV ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
10:05am, Tuesday, 10'th Jun 2025
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
06:35am, Sunday, 08'th Jun 2025
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks.
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
10:15am, Friday, 06'th Jun 2025
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
06:51pm, Thursday, 05'th Jun 2025
The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.
Make an Easy $2,852 in Passive Income By Invest $25,000 in These Dividend Stocks Today
10:30am, Thursday, 05'th Jun 2025
Key Points Put your money to work. Make it make you money. It can make you a good deal of consistent money if you invest wisely in higher-yielding Dividend King stocks. Are you ahead, or behind on ret
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)
01:00pm, Wednesday, 04'th Jun 2025
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
11:35am, Wednesday, 04'th Jun 2025
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
08:13am, Wednesday, 04'th Jun 2025
Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural,
3 Cheap Dividend Growth Stocks to Buy Right Now
05:50am, Wednesday, 04'th Jun 2025
Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effe
Bert's May 2025 Dividend Income Summary
01:43pm, Tuesday, 03'rd Jun 2025
Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for
The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with thre
